Recommended Inhaled Corticosteroids for Pediatric Persistent Asthma
For preschool children (2-4 years), use budesonide nebulizer solution as the preferred inhaled corticosteroid, and for school-aged children (≥5 years), use low-dose ICS via MDI with spacer or DPI, with budesonide and fluticasone being the primary FDA-approved options.
Preschool-Aged Children (2-4 Years)
Preferred ICS Agent and Delivery
- Budesonide nebulizer solution is the preferred first-line ICS for this age group 1
- FDA-approved for ages 1-8 years
- Most extensively studied ICS in young children and infants
- Only corticosteroid available as nebulized formulation in the US 2
Delivery Device Considerations
Children <4 years have less difficulty with:
- Nebulizer with face mask, OR
- MDI with valved holding chamber (VHC) with or without face mask 1
Dosing Strategy
- Start with low-dose ICS as preferred long-term control medication 1, 3
- Titrate to lowest dose needed to maintain control
- Benefits outweigh concerns about small, nonprogressive reduction in growth velocity 1
Alternative Agents (if budesonide unavailable)
Listed alphabetically as insufficient data exists to rank:
- Cromolyn (nebulizer preferred)
- Leukotriene receptor antagonist (montelukast) - FDA-approved as chewable tablets for 2-6 years 1
Step-Up Therapy for Inadequate Control
When low-dose ICS fails to control asthma:
- Option 1: Increase to medium-dose ICS (preferred based on dose-dependent improvements in impairment and exacerbation risk) 1, 3
- Option 2: Add leukotriene receptor antagonist to low-to-medium dose ICS before escalating to high-dose ICS to minimize side effect risk 1
Critical Caveat: LABA combined with ICS has limited data in 4-year-olds and younger, showing improvement in impairment but not risk domain 1
School-Aged Children (≥5 Years)
Preferred ICS Agents
FDA-approved options include:
- Fluticasone dry powder inhaler (>4 years) 1
- Budesonide (various formulations)
- Other ICS agents as no convincing evidence exists of important differences between currently available preparations in duration of action or side effects 4
Delivery Device Selection
- MDI with large volume spacer (enhances lung deposition and reduces oropharyngeal deposition) 4
- Dry powder inhaler (DPI) for children with adequate technique (typically >4-5 years)
- Avoid DPI unless certainty exists about technique 4
Dosing by Severity
Mild Persistent Asthma (Step 2):
- Low-dose ICS as preferred therapy 3
- Alternative options (alphabetically): cromolyn, leukotriene receptor antagonist, nedocromil, or sustained-release theophylline
Moderate Persistent Asthma (Step 3):
- Preferred: Low-dose ICS + long-acting beta2-agonist (LABA), OR medium-dose ICS 3
- Alternative: Low-dose ICS + leukotriene receptor antagonist or theophylline
Severe/Recurring Exacerbations (Step 4+):
- Preferred: Medium-dose ICS + LABA 3
- Alternative: Medium-dose ICS + leukotriene receptor antagonist or theophylline
2020 Updated Recommendations for Ages ≥5 Years
For moderate to severe persistent asthma:
- ICS-formoterol in single inhaler as both daily controller and reliever therapy (MART regimen) is now strongly recommended 5, 6
- This represents a paradigm shift from traditional fixed-dose ICS with separate SABA rescue
Critical Monitoring and Adjustment Principles
Response Assessment Timeline
- Evaluate response within 4-6 weeks 1, 3
- If no clear beneficial response AND technique/adherence are satisfactory: stop treatment and consider alternative therapies or diagnoses
- If clear beneficial response sustained ≥3 months: attempt step-down therapy 1
Growth Monitoring
- Short-term reductions in tibial growth rate demonstrated at doses >400 µg/day 4
- Cannot be extrapolated to long-term effects
- Asthma itself delays growth and puberty; catch-up growth eventually occurs 4
- Intermittent ICS (budesonide and beclomethasone) associated with 0.41 cm greater growth compared to daily treatment in pediatric trials 7
Common Pitfalls to Avoid
- Inadequate delivery device: Ensure age-appropriate device and proper technique before escalating therapy 1, 4
- Premature escalation: Verify adherence and technique before stepping up treatment 4
- Prolonged high-dose therapy: Titrate to lowest effective dose to minimize systemic effects 1, 4
- Failure to step down: Children have high rates of spontaneous remission; reassess need for continued therapy after 3 months of control 1
Special Consideration for Viral-Triggered Wheeze
For preschool children with intermittent asthma or viral-triggered wheezing:
- Preemptive high-dose intermittent ICS at onset of respiratory infection shows strong evidence for preventing exacerbations (NNT = 6) 8
- This is conditionally recommended as alternative to daily ICS in children 0-4 years with recurrent wheezing triggered by respiratory infections and no wheezing between infections 6
The evidence strongly supports ICS as the cornerstone of persistent asthma management across all pediatric age groups, with agent selection and delivery method tailored to age-specific capabilities and FDA approvals.